CJC-1295 research guide for Keroka. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
For anyone in Keroka trying to locate CJC-1295, the foundational reality is that this compound moves through online research channels. What this means for Keroka researchers is that geography is secondary to your ability to assess COA data — and those evaluation tools are accessible to anyone. Separating properly characterised CJC-1295 from the rest of the market requires three things: an HPLC chromatogram confirming ≥98% purity, mass spec data verifying the correct molecular weight, and a batch-specific endotoxin panel. The sections below cover what Keroka researchers need to know about purchasing, testing, and working with CJC-1295 for scientific research use.
The Science Behind CJC-1295
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Keroka researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
CJC-1295 Purchasing Guide
Quality CJC-1295 sourcing begins with a useful first test: does this vendor publish batch-specific COAs proactively? Those who make this data freely available are signalling genuine quality commitment. Mass spectrometry in the COA confirms that the main HPLC peak is actually CJC-1295 and not another compound with similar chromatographic behaviour — HPLC purity alone provides no identity confirmation. The combination of community consensus and independent COA review is the most reliable sourcing approach — community feedback surfaces recurring issues no single purchase reveals, and vice versa. For Keroka researchers making a first CJC-1295 purchase: verify the vendor against this framework, begin with a small order, and verify batch traceability on arrival before use.
Order CJC-1295 — ships to Keroka
COA-verified · International tracking · Research grade
CJC-1295 is sold for research purposes only and is not approved for human therapeutic use by the FDA or comparable health authorities — all information here is provided for educational purposes. Proper handling of CJC-1295 requires sterile reconstitution technique — prep pad-cleaned septum, single-use needles, uncontaminated workspace — and temperature control throughout the entire workflow. Endotoxin testing in the CJC-1295 COA is not optional — gram-negative bacterial endotoxins can trigger serious inflammatory reactions at very low concentrations, and no discount compensates for this missing data. PubMed and related preprint servers are the primary literature resources for CJC-1295 research; focus on peer-reviewed publications with documented compound quality over unreviewed preprints or forum reports.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
